You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

JNJ-42756493

Showing 1 - 25 of 435
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Tumor Trial in China, Korea, Republic of, Taiwan (Erdafitinib)

Active, not recruiting
  • Neoplasm
  • Beijing, China
  • +5 more
Jan 31, 2023

Healthy Trial in Merksem (Erdafitinib, Carbamazepine)

Completed
  • Healthy
  • Merksem, Belgium
    Clinical Pharmacology Unit
Jul 14, 2022

Recurrent Glioblastoma, IDH-Wildtype, Recurrent WHO Grade 2 Glioma, Recurrent WHO Grade 3 Glioma Trial (Biospecimen Collection,

Not yet recruiting
  • Recurrent Glioblastoma, IDH-Wildtype
  • +2 more
  • Biospecimen Collection
  • +2 more
  • (no location specified)
May 13, 2023

Urinary Bladder Tumors, Receptors, Fibroblast Growth Factor Trial in Japan (Erdafitinib Intravesical Delivery System)

Not yet recruiting
  • Urinary Bladder Neoplasms
  • Receptors, Fibroblast Growth Factor
  • Erdafitinib Intravesical Delivery System
  • Kanagawa, Japan
  • +3 more
Jan 27, 2023

Castration-Resistant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen

Recruiting
  • Castration-Resistant Prostate Carcinoma
  • +7 more
  • Biopsy
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 12, 2022

Multiple Myeloma, Relapsed/Refractory Trial in Toronto (JNJ-42756493, Dexamethasone)

Terminated
  • Multiple Myeloma
  • Relapsed/Refractory
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Sep 15, 2020

Bladder Carcinoma, Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma Trial in Toronto (biological, procedure,

Recruiting
  • Bladder Carcinoma
  • +7 more
  • Atezolizumab
  • +5 more
  • Toronto, Ontario, Canada
    University Health Network Princess Margaret Cancer Center LAO
Nov 8, 2022

Hepatic Impairment Trial in Kiel, Munchen (Erdafitinib)

Terminated
  • Hepatic Impairment
  • Kiel, Germany
  • +1 more
Mar 26, 2021

Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter

Recruiting
  • Locally Advanced Bladder Urothelial Carcinoma
  • +18 more
  • Los Angeles, California
  • +2 more
Jun 28, 2022

Carcinoma, Hepatocellular Trial in China, Korea, Republic of, Taiwan (JNJ-42756493 (erdafitinib))

Completed
  • Carcinoma, Hepatocellular
  • JNJ-42756493 (erdafitinib)
  • Changchun, China
  • +9 more
Feb 17, 2020

Relapsed Refractory Multiple Myeloma Trial in United States (Abemaciclib, dexamethasone, ixazomib, pomalidomide, Enasidenib,

Recruiting
  • Relapsed Refractory Multiple Myeloma
  • Abemaciclib, dexamethasone, ixazomib, pomalidomide
  • +7 more
  • Phoenix, Arizona
  • +16 more
Sep 9, 2021

Lung Cancer, NSCLC, Pulmonary Tumor Trial in Germany (ERDAFITINIB)

Unknown status
  • Lung Cancer
  • +4 more
  • Gauting, Bavaria, Germany
  • +10 more
Nov 11, 2020

Tumors, Lymphoma, Adenocarcinoma Trial in Kashiwa, Matsuyama, Tokyo (Part 1: JNJ-42756493, Part 2: JNJ-42756493)

Completed
  • Neoplasms
  • +3 more
  • Part 1: JNJ-42756493
  • Part 2: JNJ-42756493
  • Kashiwa, Japan
  • +2 more
May 13, 2019

Tumor or Lymphoma Trial in France, Spain, United States (JNJ-42756493: Part 1, JNJ-42756493: Part 2, JNJ-42756493: Part 3)

Completed
  • Tumor or Lymphoma
  • JNJ-42756493: Part 1
  • +3 more
  • Birmingham, Alabama
  • +36 more
May 24, 2019

Advanced Cancers and FGFR Genetic Alterations Trial (Erdafitinib)

Approved for marketing
  • Advanced Cancers and FGFR Genetic Alterations
  • (no location specified)
May 9, 2019

Advanced Solid Tumor Trial in Worldwide (Erdafitinib)

Recruiting
  • Advanced Solid Tumor
  • Tucson, Arizona
  • +199 more
Jan 27, 2023

Urinary Bladder Tumors Trial in Worldwide (Erdafitinib, Investigator Choice (Gemcitabine), Investigator Choice (Mitomycin C))

Recruiting
  • Urinary Bladder Neoplasms
  • Tucson, Arizona
  • +178 more
Mar 24, 2022

Advanced Prostate Cancer Trial in Lyon, Villejuif, Rotterdam (JNJ-78278343, JNJ-87189401)

Not yet recruiting
  • Advanced Prostate Cancer
  • Lyon, France
  • +2 more
Oct 18, 2023

Myeloproliferative Disorders, Essential Thrombocythemia, Tumors Trial (JNJ-88549968)

Not yet recruiting
  • Myeloproliferative Disorders
  • +3 more
  • (no location specified)
Nov 21, 2023

Advanced Malignant Solid Tumor, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma Trial in

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +44 more
  • Biopsy
  • +23 more
  • Birmingham, Alabama
  • +166 more
Feb 2, 2023

Lymphoma, Non-Hodgkin Trial (JNJ-87801493, JNJ-80948543, JNJ-75348780)

Not yet recruiting
  • Lymphoma, Non-Hodgkin
  • (no location specified)
Nov 15, 2023

Healthy Trial in Lincoln (JNJ-68179280, Placebo)

Recruiting
  • Healthy
  • Lincoln, Nebraska
    Celerion
Jan 17, 2023

Prostatic Tumors, Metastatic Castration-Resistant Prostate Cancer Trial in Worldwide (Abiraterone Acetate, Prednisone,

Active, not recruiting
  • Prostatic Neoplasms
  • Metastatic Castration-Resistant Prostate Cancer
  • Abiraterone Acetate
  • +2 more
  • Los Angeles, California
  • +6 more
Jan 18, 2023

Metastatic Castration-resistant Prostate Tumors Trial in Australia, Korea, Republic of, United States (JNJ-78278343, Cetrelimab)

Not yet recruiting
  • Metastatic Castration-resistant Prostate Neoplasms
  • Sarasota, Florida
  • +7 more
Apr 6, 2023

Tumors, Solid Tumor, Adult, Non-Hodgkin Lymphoma Trial in Worldwide (JNJ-64619178)

Active, not recruiting
  • Neoplasms
  • +3 more
  • Sarasota, Florida
  • +17 more
Jan 27, 2023